Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

FDA IND Clearance Advances Eloxx in Nonsense-Mutation ADPKD Trial

Oct 29, 2026, 8:23 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

IND clearance is a positive regulatory milestone enabling US trial execution and potential accelerated-path discussions, supporting long-run value; however, visibility to cash flow remains limited until trial data and potential designations materialize.

AI summary

What happened, with direct paths to the underlying reporting

FDA cleared Eloxx's IND for exaluren in nonsense-mutation ADPKD, enabling EXPRESS Phase 2 trial initiation. The study will enroll about 60 adults with PKD1/PKD2 nonsense mutations over 52 weeks, with htTKV growth as the primary endpoint; first dosing is targeted for 3Q 2027 and topline data in 1H 2029. The FDA highlighted potential for Breakthrough Therapy designation and accelerated approval pathways based on htTKV outcomes.

FDA clears IND for exaluren in nonsense-mutation ADPKD.
EXPRESS Phase 2 plans ~60 patients, 52 weeks, htTKV primary endpoint.
First patient dosing planned for 3Q2027; topline 1H2029.
FDA notes htTKV could support Breakthrough Therapy or accelerated approval.
Orphan designation in US/Europe; potential future milestones.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.